Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø

ºîÀ®¡§ 2001/1/15 ÏÉÌî ¹°ÌÀ

¥Ç¡¼¥¿Èֹ桡¡¡¡¡¡§030228
¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤Ë¤è¤ë´â¤ÎÊü¼ÍÌȱּ£ÎÅ
ÌÜŪ¡¡¡¡¡¡¡¡¡¡¡¡¡§¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤Çɸ¼±¤·¤¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤˤè¤ë´â¼£ÎŤξҲð
Êü¼ÍÀþ¤Î¼ïÊÌ¡¡¡¡¡§¥¢¥ë¥Õ¥¡Àþ,¥Ù¡¼¥¿Àþ
±þÍÑʬÌî¡¡¡¡¡¡¡¡¡§°å³Ø¡¢¼£ÎÅ

³µÍס¡¡¡¡¡¡¡¡¡¡¡¡§
¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤Çɸ¼±¤µ¤ì¤¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤ¬¡¢¿·¤·¤¤¥¿¥¤¥×¤Î¹³¤¬¤óºÞ¤È¤·¤Æ¸¦µæ¤µ¤ì¤Æ¤¤¤ë¡£¤³¤ì¤Ï¡¢Âγ°¤«¤éÊü¼ÍÀþ¤ò¾È¼Í¤¹¤ë½¾Íè¤ÎÊü¼ÍÀþÎÅË¡¤È°Û¤Ê¤ê¡¢¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤Çɸ¼±¤µ¤ì¤¿¹³ÂΤòÂÎÆâ¤ËÅêÍ¿¤·¡¢ÂÎÆ⤫¤éÉÂÊÑÉô¤ò¾È¼Í¤¹¤ë¼£ÎÅË¡(Êü¼ÍÌȱּ£ÎÅ)¤Ç¤¢¤ë¡£¸½ºß¡¢¼ÂÍѲ½¤µ¤ì¤Ä¤Ä¤¢¤ëÊü¼ÍÌȱּ£ÎŤϡ¢131I¤ä90Y¤Ê¤É¤Î¥Ù¡¼¥¿ÀþÊü½Ð³Ë¼ï¤òÍѤ¤¡¢¤½¤ÎÂоݤâÊü¼ÍÀþ´¶¼õÀ­¤¬¹â¤¤¼ðáç¡¢Èó¥Û¥¸¥­¥ó¥ê¥ó¥Ñ¼ð¤Ë¸ÂÄꤵ¤ì¤Æ¤¤¤ë¡£¥¢¥ë¥Õ¥¡Àþ¤Ï¡¢¥Ù¡¼¥¿Àþ¤ËÈæ¤Ù¤Æ¤Ï¤ë¤«¤Ë¹â¤¤À¸Êª³ØŪ¸ú²Ì¤ò»ý¤Á¡¢¼£ÎÅÂоݤϤè¤ê¹­¤¤²ÄǽÀ­¤¬¤¢¤ë¤¿¤á¡¢¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤òÍøÍѤ¹¤ë¸¦µæ¤¬ÃÏÆ»¤Ë³¤±¤é¤ì¤Æ¤¤¤ë¡£

¾ÜºÙÀâÌÀ¡¡¡¡¡¡¡¡¡§

1. ¥¢¥ë¥Õ¥¡Àþ¤ÎÀ¸Êª³ØŪ¸ú²Ì

¡¡¥¢¥ë¥Õ¥¡Àþ¤Ï¡¢Ã±°ì¹â¥¨¥Í¥ë¥®¡¼¤Î¥Ø¥ê¥¦¥à¸¶»Ò³Ë(4He)¤Ç¤¢¤ê¡¢Êü¼ÍÀ­Æ±°Ì¸µÁÇ(RI)¤¬¥¢¥ë¥Õ¥¡²õÊѤ¹¤ëºÝ¤ËÊü½Ð¤µ¤ì¤ë¡£¸½ºß¥¢¥ë¥Õ¥¡²õÊѤ¹¤ëRI¤Ï¡¢¼ç¤Ë¸¶»ÒÈÖ¹æ82°Ê¾å¤Î½Å¤¤¸µÁǤǡ¢Ìó100¼ï¤Û¤ÉÃΤé¤ì¤Æ¤¤¤ë¡£¥¢¥ë¥Õ¥¡Àþ¤ÎºÝΩ¤Ã¤¿ÆÃħ¤Ï¡¢¤½¤Î¹â¤¤Àþ¥¨¥Í¥ë¥®¡¼ÉÕÍ¿(linear energy transfer:LET)¤Èû¤¤ÈôÄø¤Ë¤¢¤ë¡£Î㤨¤Ð¡¢Êü¼ÍÌȱּ£ÎŤÇÂåɽŪ¤Ê¥Ù¡¼¥¿³Ë¼ï¤Ç¤¢¤ë90Y¤È¥¢¥ë¥Õ¥¡³Ë¼ï¥¢¥¹¥¿¥Á¥ó-211(211At)¤òÈæ³Ó¤¹¤ë¤È¼¡¤Î¤è¤¦¤Ë¤Ê¤ë¡§
¡¡¡¡¡¡¡¡¡¡¡¡¡¡LET(keV/¦Ìm) À¸ÂÎÁÈ¿¥Ãæ¤ÎÊ¿¶ÑÈôÄø(¦Ìm)
¡¡¡¡Y-90¡§¡¡¡¡¡¡0.2¡¡¡¡¡¡¡¡¡¡¡¡¡¡ 3960
¡¡¡¡At-211¡§¡¡¡¡97¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡70

¡¡211At¤ÎLET¤Ï90Y¤ÈÈæ¤Ù¤Æ500ÇܤۤÉÂ礭¤¤¤¬¡¢Ê¿¶ÑŪ¤Ë¸À¤Ã¤Æ¥¢¥ë¥Õ¥¡Àþ¤ÎLET¤Ï¥Ù¡¼¥¿Àþ¤ÎLET¤Î400ÇÜ(80 keV/¦Ìm vs 0.2 keV/¦Ìm)¤Ï¤¢¤ë¡£¤½¤Î¤¿¤á¡¢Êü½ÐÆÃÀ­¤Ë¤â°Í¸¤¹¤ë¤¬¡¢¥¢¥ë¥Õ¥¡Àþ¤ÎºÙ˦ÉԳ貽(Ã×»à)ºîÍѤËÂФ¹¤ëÀ¸Êª³ØŪ¸ú²ÌÈæ(RBE)¡ö¡Ë¤Ï£³¡Á£·¤È¤Ê¤ë¡£In vitroºÙ˦¼Â¸³¤Î·ë²Ì¤Ë¤è¤ë¤È¡¢¤â¤·ºÙ˦ɽÌ̤ǥ¢¥ë¥Õ¥¡²õÊѤ¬µ¯¤­¥¢¥ë¥Õ¥¡Àþ¤¬ºÙ˦³Ë¤òÄ̲᤹¤ë¤È¡¢¤¿¤Ã¤¿£±¸Ä¤Î¥¢¥ë¥Õ¥¡Î³»Ò¤ÇºÙ˦¤ò»àÌǤµ¤»¤ë¤³¤È¤¬²Äǽ¤È¿äÄꤵ¤ì¤ë¡£¤·¤«¤·¡¢¥Ù¡¼¥¿Àþ¤Î¾ì¹ç¤Ï¡¢¤³¤ì¤¬1,000¡Á10,000¸Ä¤ÏɬÍפȤʤ롣¡È°ìÂÇɬ»¦¡É¤¬¥¢¥ë¥Õ¥¡Àþ¤Ê¤é¡¢¡È¥¸¥ï¥¸¥ï¤È»¦¤¹¡É¤Î¤¬¥Ù¡¼¥¿Àþ¤È¤¤¤¨¤ë¡£¡Ê¤½¤Î¤è¤¦¤Ê¥Ù¡¼¥¿Àþ¤Ç¤â¡¢Êü¼ÍÀþ¼£ÎŤËÈÆÍѤµ¤ì¤ë¥¬¥ó¥ÞÀþ¤è¤êRBE¤¬¹â¤¯¼£ÎŸú²Ì¤Ï¤è¤¤¡Ë

*)À¸Êª³ØŪ¸ú²ÌÈæ(relative biological effectiveness¡§RBE)
°Û¤Ê¤ëÀþ¼Á¤ä¥¨¥Í¥ë¥®¡¼¤ÎÅÅÎ¥Êü¼ÍÀþ¤Ë¤è¤ëµÛ¼ýÀþÎ̤ÎÀ¸Êª³ØŪ¸ú²Ì¤òÈæ³Ó¤¹¤ë·¸¿ô¡£ÆÃÄê¤ÎÀ¸Êª¡¢Â¡´ï¤¢¤ë¤¤¤ÏÁÈ¿¥¤ËÂФ·¤ÆƱ°ì¤ÎÀ¸Êª³ØŪ¸ú²Ì¤ò¤â¤¿¤é¤¹¤è¤¦¤Ê¡¢Åö³ºÊü¼ÍÀþ¤È´ð½àÊü¼ÍÀþ¤ÎµÛ¼ýÀþÎ̤ÎÈæ¤ÈÄêµÁ¤µ¤ì¤ë¡£

¡¡¥¢¥ë¥Õ¥¡Àþ¤ÎÈôÄø¤Ï¤­¤ï¤á¤Æû¤¯¡¢Î㤨¤Ð211At¤Î70¦Ìm¤Ï¤ª¤è¤½ºÙ˦10¸Äʬ¤ÎŤµ¤Ç¤¢¤ë¡£¤³¤ì¤Ï¡¢¥¢¥ë¥Õ¥¡Àþ¤ÎÃ×»àºîÍѤòºÇÂç¸Â¤ËÍøÍѤ¹¤ë¤Ë¤ÏÂγ°¾È¼Í¤ÏÉÔŬÀڤǤ¢¤ê¡¢¥¢¥ë¥Õ¥¡³Ë¼ï¤ò²¿¤é¤«¤ÎÊýË¡¤Ç¼ðáç¤Ê¤É¤ÎÉÂÊÑÉô°Ì¤ËÁªÂòŪ¤Ë±¿¤ÖÊýË¡¤¬É¬¿Ü¤Ç¤¢¤ë¤³¤È¤ò°ÕÌ£¤¹¤ë¡£¤½¤³¤Ç½Ð¤Æ¤­¤¿¤Î¤¬¡¢1980ǯÂå¤ËµÞ®¤ËȯŸ¤·¤¿¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤòÍøÍѤ¹¤ë¥¢¥¤¥Ç¥¢¤Ç¤¢¤ë¡£¥¢¥ë¥Õ¥¡³Ë¼ï¤ò¼ðáç¤ËÆðÛŪ¤Ê¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤ˷ë¹ç¤·¡¢¤½¤ì¤òÂÎÆâ¤ËÅêÍ¿¤·¡¢¹³ÂΤÎÎϤò¤«¤ê¤Æ¼ðáçÁÈ¿¥¤Þ¤Ç±¿È¡Á¾È¼Í¤¹¤ë¡¢Â¨¤ÁÊü¼ÍÌȱּ£ÎŤǤ¢¤ë¡£¤³¤Î¥¢¥×¥í¡¼¥Á¤Ë´ð¤Å¤¯¸¦µæÏÀʸ¤¬¡¢¤¹¤Ç¤Ë¤¤¤¯¤Ä¤«È¯É½¤µ¤ì¤Æ¤¤¤ë¡£

2. Êü¼ÍÌȱÖÎÅË¡¤Ø±þÍѤ¬¹Í¤¨¤é¤ì¤ë¥¢¥ë¥Õ¥¡³Ë¼ï

¡¡Ìó100¼ï¤Î¥¢¥ë¥Õ¥¡³Ë¼ï¤Î¤¦¤Á¼ÂºÝ¤ËÎ×¾²»ÈÍѤ¹¤ë¤Ë¤Ï¡¢Â¿¤¯¤ÎÍ×µá¤òËþ¤¿¤¹É¬Íפ¬¤¢¤ë¡£¤½¤ì¤é¤òÎóµó¤¹¤ë¤È¡¢
­¡Å¬Àڤʼ£ÎŸú²Ì¤òÍ¿¤¨¤ëȾ¸º´ü¤ò»ý¤Ã¤Æ¤¤¤ë¤³¤È¡£¡ÊȾ¸º´ü¤Ï¡¢Ã»¤¹¤®¤Æ¤âŤ¹¤®¤Æ¤â¤¤¤±¤Ê¤¤¡Ë
­¢°ÂÄêŪ¤ÊÌôºÞ¤ËÀ½Â¤¤·ÆÀ¤ëºøÂβ½³ØŪÆÃÀ­¤òÍ­¤¹¤ë¤³¤È¡£
­£²õÊѤηë²ÌÀ¸¤º¤ë̼³Ë¼ï¤¬¡¢°ÂÁ´À­¾åÀ¸ÂÎÆâ¤ÇÌäÂê¤ò°ú¤­µ¯¤³¤µ¤Ê¤¤¤³¤È¡£¡ÊȾ¸º´ü¤ÎŤ¤Ì¼³Ë¼ï¤¬¹ü¤Ê¤É¤ÎÆÃÄê¡´ï¤Ë½¸ÀѤ¹¤ì¤Ð¡¢¹ü¿ñÆÇÀ­¤¬È¯¸½¤·Â礭¤ÊÌäÂê¤È¤Ê¤ë¡Ë
­¤¥¤¥á¡¼¥¸¥ó¥°¤ËŬ¤·¤¿¥¨¥Í¥ë¥®¡¼¤Î¥¬¥ó¥ÞÀþ¤òÊü½Ð¤·¡¢¤«¤Ä¤½¤ì¤ËÉÔŬÀڤʥ¬¥ó¥ÞÀþ¤ÏÊü½Ð¤·¤Ê¤¤¤³¤È¡£¡ÊÅêÍ¿¤¹¤ë¤Ë¤Ï¡¢Á°¤â¤Ã¤ÆÀþÎÌʬÉÛ·×»»¤¬É¬Íס£¤½¤Î¤¿¤á¤Ë¤Ï¡¢¥¤¥á¡¼¥¸¥ó¥°¤Ç¤­¤ë¤³¤È¤¬É¬¿Ü¾ò·ï¤È¤Ê¤ë¡£¡Ë
­¥¼Ò²ñŪ¤Ë¼õ¤±Æþ¤ì²Äǽ¤Ê²Á³Ê¤Ç¡¢É¬Í×Î̤òËþ¤¿¤¹À¸»ºÊýË¡¤¬¤¢¤ë¤³¤È¡£¡Ê˾¤Þ¤·¤¯¤Ï¡¢¥¸¥§¥Í¥ì¡¼¥¿Êý¼°¤¢¤ë¤¤¤Ï¥µ¥¤¥¯¥í¥È¥í¥óÀ¸»º¤¬¤Ç¤­¤ë¤³¤È¡Ë

¤È¤Ê¤ë¡£¸½»þÅÀ¤Ç¤Ï°Ê²¼¤Îɽ¤Ë¼¨¤¹¤è¤¦¤Ê¥¢¥ë¥Õ¥¡³Ë¼ï¤¬¸õÊä¤È¤·¤Æ¸¡Æ¤¤µ¤ì¤Æ¤¤¤ë¡£

ɽ1¡¡Êü¼ÍÌȱּ£ÎŤؤαþÍѤ¬¸¡Æ¤¤µ¤ì¤Æ¤¤¤ë¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï
¥¢¥ë¥Õ¥¡Êü½Ð³Ë¼ï¡¡¡¡È¾¸º´ü       À¸»ºÊýË¡
Astatine-211¡¡¡¡¡¡¡¡7.21 »þ´Ö    ¸¶»Òϧ¡¢¥µ¥¤¥¯¥í¥È¥í¥ó
Bismuth-212         60.55 ʬ     ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Bismuth-213         45.6 ʬ      ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Lead-212            10.64 »þ´Ö   ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Actinium-225        10.0 Æü      ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Fermium-255         20.1 »þ´Ö    ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Radium-223          11.4 Æü      ¸¶»Òϧ¢ª¥¸¥§¥Í¥ì¡¼¥¿
Terbium-149         4 »þ´Ö       ¸¶»Òϧ¡¢¥·¥ó¥¯¥í¥È¥í¥ó

¡¡¤³¤ì¤é¤Î³Ë¼ï¤Î²õÊÑ·ÏÎó¤ò°Ê²¼¿Þ£±¤Ë¼¨¤¹¡£É½Ãæ¤Î³Ë¼ï¤Ï¡¢²õÊÑ·ÏÎó¤Î²¼Î®¤Ë°ÌÃÖ¤·¤Æ¤ª¤ê¡¢ÂÎÆâ¤ËĹ´ü´Ö»Äα¤·¤ÆÊü¼ÍÀþ¤ò½Ð¤·Â³¤±¤ë¤³¤È¤¬¾¯¤Ê¤¤³Ë¼ï¤¬ÁªÂò¤µ¤ì¤Æ¤¤¤ë¡£


¿Þ1¡¡¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï¤ÎÊø²õ·ÏÎó¡Ê¸¶ÏÀʸ1¤è¤ê°úÍÑ¡Ë


3. ¥¢¥ë¥Õ¥¡³Ë¼ïɸ¼±¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤÎÎ×¾²¤Ø¤Î±þÍÑ

¡¡1996ǯ¡¢¥¢¥ë¥Õ¥¡³Ë¼ïɸ¼±¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤ¬½é¤á¤Æ¿ÍÂΤËÅêÍ¿¤µ¤ì¤¿¡£¤½¤ì¤Ï¡¢°äÅÁ»Ò¹©³ØŪ¤Ë¥Ò¥È·¿²½¤µ¤ì¤¿IgG1¹³ÂÎ(HuM195)¤Ë¡¢Æó´±Ç½À­¥­¥ì¡¼¥ÈºÞDTPA¤ò²ð¤·¤Æ¥Ó¥¹¥Þ¥¹-213(213Bi)¤ò·ë¹ç¤·¤¿¤â¤Î¤Ç¤¢¤Ã¤¿¡£HuM195¤Ï¡¢¥Ò¥È¹ü¿ñÀ­Çò·ìɤǹâȯ¸½¤¹¤ëCD33¹³¸¶¤ËÆðÛŪ¤Ë·ë¹ç¤·¡¢¹³¸¶¤Ë·ë¹ç¤¹¤ë¤Èľ¤Á¤ËºÙ˦Æâ¤Ë¼è¤ê¹þ¤Þ¤ì¤ë¡£É¸¼±¹³ÂΤÎÈæÊü¼Íǽ(¹³ÂÎmg¤¢¤¿¤ê¤ÎÊü¼ÍǽÎÌ)¤Ï¡¢740MBq/mg¤Ç¤¢¤ê¡¢Ä̾ïãÀ®²Äǽ¤Ê¥ì¥Ù¥ë¤È¤¤¤¨¤ë¡£
¡¡CD33¤òȯ¸½¤¹¤ëHL60ºÙ˦¤òÍѤ¤¤¿in vitroºÙ˦¼Â¸³¤Î·ë²Ì¡¢ºÙ˦¤Î£µ£°¡óÃ×»à213BiÎ̤ϡ¢Ê¿¶Ñ¤·¤ÆºÙ˦£±¸Ä¤¢¤¿¤ê213Bi£²¸Ä¤Ç¤¢¤ê¡¢Èó¾ï¤ËÍ­¸ú¤Ç¤¢¤ë¤³¤È¤¬Ê¬¤«¤ë¡£
¡¡In vitro¼Â¸³¤Î·ë²Ì¤ò¤â¤È¤Ë¡¢£¹¿Í¤ÎºÆȯ¤Þ¤¿¤ÏµÞÀ­¹ü¿ñÀ­Çò·ìÉ´µ¼Ô¤Ë¡¢Êü¼ÍǽÎ̤ǹç·×10.4, 15.5, 20.7 MBq/kg(ÅêÍ¿ÁíÎÌ¡á555¡Á1,591 MBq/¿Í)¤¬3¡Á6²ó/2¡Á4Æü¤Ëʬ¤±¤ÆÅêÍ¿¤µ¤ì¤¿¡£µÞÀ­¤Î½ÅÆƤÊÉûºîÍѤÏȯ¸½¤·¤Ê¤«¤Ã¤¿¤¬¡¢¹ü¿ñÍÞÀ©¤¬£²½µ´Ö¤Û¤É´Ñ»¡¤µ¤ì¤¿¡£¹ü¿ñÍÞÀ©¤Ï¡¢¹³¤¬¤óºÞ¼£ÎŤǤϰìÈ̤˸«¤é¤ì¤ëÉûºîÍѤǤ¢¤ë¡£¤³¤Î¤¦¤Á¼£ÎÅÀ®ÀÓ¤òɾ²Á¤¹¤ë¤³¤È¤¬¤Ç¤­¤¿£µÎã¤Ç¤Ï¡¢Á´Îã¤ÇËö¾¿·ìÃæ¤Î¹ü¿ñÀ­Çò·ìɺÙ˦¤Î¸º¾¯¤¬¸«¤é¤ì¡¢¹ü¿ñÆâ¤ÎÇò·ìɺÙ˦¤â¸º¾¯¤·¤¿¡£
¡¡¤³¤Î¸¦µæ¤Ë¤è¤ê¡¢ÍýÏÀŪ¤Ëͽ¬¤µ¤ì¤¿¥¢¥ë¥Õ¥¡Êü½Ð³Ë¼ï¤Î¼£ÎŸú²Ì¤¬½é¤á¤Æ¥Ò¥È¤Ç¼ÂºÝ¤Ë³Îǧ¤µ¤ì¤¿¡£

¥³¥á¥ó¥È¡¡¡¡¡¡¡¡¡§
¥¢¥ë¥Õ¥¡³Ë¼ïɸ¼±¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤαþÍѤËɬÍפÊÃ챤ÈÍýÏÀ¤Ï¡¢¤³¤Î10ǯ´Ö¤ÇÂ礭¤¯¿ÊÊ⤷¤¿¤È¤¤¤¨¤ë¡£¤·¤«¤·¡¢¼ÂºÝ¤Ë¾¦¶È²½¤Ë»ê¤ë¤Þ¤Ç¤ÎÆ»¤Ï¸±¤·¤¤¡£¥´¡¼¥ë¤Ë¤¿¤É¤êÃ夯¤Ë¤Ï¡¢¾¯¤Ê¤¯¤È¤â°Ê²¼¤Î¤è¤¦¤Êµ¿Ìä¤ä²ÝÂê¤ËÅú¤¨¤ëɬÍפ¬¤¢¤ë¡£

­¡¥¢¥ë¥Õ¥¡³Ë¼ï¤Î¾¦¶ÈÀ¸»º¤ò²Äǽ¤Ë¤¹¤ëÊýË¡¤Ï¡¢¥¸¥§¥Í¥ì¡¼¥¿Êý¼°¤«¡¢¤½¤ì¤È¤â¥µ¥¤¥¯¥í¥È¥í¥óÀ¸»º¤«¡©¡¡²Á³ÊµÚ¤ÓÀ¸»ºÎ̤ϡ¢¼Ò²ñŪ¤Ë¼õ¤±Æþ¤ì²Äǽ¤«¡©
­¢¥¢¥ë¥Õ¥¡³Ë¼ïɸ¼±¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂΤǡ¢Â礭¤Ê²ô¤Î¼ðáç¤ò¼£ÎŤǤ­¤ë¤«¡¢¤½¤ì¤È¤â¾¤ÎÊýË¡¤Ç¤â²Äǽ¤ÊÁá´ü¤Î¾®¤µ¤Ê¼ðáç¤Ë¸ÂÄꤵ¤ì¤ë¤Î¤«¡©
­£¼ðáç¤Î¥³¥ó¥È¥í¡¼¥ë¤Ï¡¢Â¾¤Î¡´ï¤ä¹ü¿ñ¤Ø¤Î½ÅÂç¤ÊÉûºîÍѤʤ·¤Ë²Äǽ¤«¡©
­¤¥¢¥ë¥Õ¥¡³Ë¼ï¤Ï¡¢¤¢¤é¤æ¤ëÅÀ¤Ë¤ª¤¤¤Æ°ÂÁ´À­(²½³ØŪÆÇÀ­¡¢Êü¼ÍÀþȯ¤¬¤ó)¤ËÌäÂê¤Ê¤¤¤«¡©

¸¶ÏÀʸ£± Data source 1¡§
Cellular dose conversion factors for alpha-particle-emitting radionuclides of interest in radionuclide therapy.
K. A. Hamacher, R.B. Den, E.I. Den & G. Sgouros.

J. Nucl. Med. 42, p.1216-1221, 2001

»²¹Í»ñÎÁ£± Reference 1¡§
Radioimmunotherapy with alpha-emitting nuclides
M.R. McDevitt, G. Sgouros, R.D. Finn, J.L.Humm et al.

Eur. J. Nucl. Med. 25, p.1341-1351, 1998

»²¹Í»ñÎÁ£² Reference 2¡§
Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus.
M.R. Raju, Y. Eisen, S. Carpenter & W.C. Inkret.

Radiat. Res. 128, p.204-209, 1991

»²¹Í»ñÎÁ£³ Reference 3¡§
Radionuclides and carrier molecules for therapy.
J. Zweit.

Phys. Med. Biol. 41, p.1905-1914, 1996

»²¹Í»ñÎÁ£´ Reference 4¡§
Radioimmunotherapy with alpha particle-emitting radioimmunoconjugates
M.R. Zalutsky, & D.D. Binger.

Acta Oncol. 35, p.373-379, 1996

»²¹Í»ñÎÁ£µ Reference 5¡§
Potential use of alpha emitting radionuclides in the treatment of cancer.
D.S. Wilbur

Antibody Immunoconj. Radiopharm. 4, p.85-97, 1991

»²¹Í»ñÎÁ£¶ Reference 6¡§
Normal organ dosimetry of leukemia patients treated with HuM195 labeled with the alpha particle emitter Bismuth-213.
A.M. Ballangrud, J.L. Humm, M.R. McDevitt, R.D. Finn et al.

J. Nucl. Med. 39(May Suppl), Abstract. No.849, 1998

¥­¡¼¥ï¡¼¥É¡§Êü¼ÍÌȱּ£ÎÅ, Êü¼ÍÀ­°åÌôÉÊ, ¥â¥Î¥¯¥í¡¼¥Ê¥ë¹³ÂÎ, ¼ðáç, ¹ü¿ñÀ­Çò·ìÉÂ, ¥¢¥ë¥Õ¥¡ÀþÊü½Ð³Ë¼ï, 211At(¥¢¥¹¥¿¥Á¥ó£²£±£±), 212Bi¡Ê¥Ó¥¹¥Þ¥¹£²£±£²¡Ë, 213Bi¡Ê¥Ó¥¹¥Þ¥¹£²£±£³¡Ë, 212Pb¡Ê±ô£²£±£²¡Ë, 225Ac¡Ê¥¢¥¯¥Á¥Ë¥¦¥à£²£²£µ¡Ë, 255Fm¡Ê¥Õ¥§¥ë¥ß¥¦¥à£²£µ£µ¡Ë, 223Ra¡Ê¥é¥¸¥¦¥à£²£²£³¡Ë, 149Tb¡Ê¥Æ¥ë¥Ó¥¦¥à£±£´£¹¡Ë, CD33
radioimmunotherapy, radiopharmaceutical, monoclonal antibody, tumor, myelocytic, myelogenic, leukemia, alpha particle-emitter,
ʬÎॳ¡¼¥É¡§030502, 030301, 030403

Êü¼ÍÀþÍøÍѵ»½Ñ¥Ç¡¼¥¿¥Ù¡¼¥¹¤Î¥á¥¤¥ó¥Ú¡¼¥¸¤Ø